



Alaska Medical Assistance DUR Committee Meeting
Friday, November 21, 2014

Agenda

- (1) Review of minutes from the last meeting
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
- (4) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - b. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. FDA Indication Changes
 - ii. FDA Label Changes
 - iii. Periodic Review
 1. Botulinum toxin
 2. Hepatitis C, Direct Acting Agents
 3. Intuniv
 - c. Proposed New Prior Authorizations, Quantity Limits, Edits
 - i. Imbruvica
 - ii. Zydelig
 - iii. Entyvio
 - iv. Stelara
 - v. Testosterone Replacement Therapy

<<Break>>

- (5) Past Intervention Informational Updates
 - a. Long-acting opioids step-edit
- (6) FDA/DEA Updates
 - a. Xolair
 - b. Lunesta
- (7) FAERS Reports
 - a. Apr – Jun 2014 report
- (8) Quality Measures
- (9) Standing Reviews
- (10) End of Meeting